Alternative Cell Death Modes in Regulating Cancer Stem Cells and Therapeutic Strategies
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 25 December 2024 | Viewed by 345
Special Issue Editors
Interests: alternative cell death mode; cancer cell metabolism; natural product; tumor microenvironment; immune mechanism; cellular basis of cancer therapy resistance; small molecule-based therapeutics
2. Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore
Interests: regulation of cell death signaling in cancer cells; reactive oxygen species and cell fate; Bcl-2 family and mitochondrial metabolism; protein phosphatase PP2A and cancer; autophagy and cancer; experimental therapeutics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The intricate interplay between alternative cell death modes and their impact on cancer stem cells (CSCs) opens new opportunities in the realm of cancer research. In this Special Issue of Cancers, titled "Alternative Cell Death Modes in Regulating Cancer Stem Cells and Therapeutic Strategies", we aim to explore the multifaceted roles of unconventional cell death pathways in shaping CSC biology.
Traditional apoptosis has been extensively studied, but emerging evidence suggests the involvement of non-apoptotic cell death modes like necroptosis, ferroptosis, and autophagy in modulating the fate of CSCs. Understanding how these alternative cell death mechanisms intersect with CSC regulation holds great promise for advancing our comprehension of tumorigenesis.
We invite original research articles and reviews delving into the intricate connections between alternative cell death modes and CSC dynamics. Contributions may span investigations using various cancer models, encompassing in vitro and in vivo approaches across diverse cancer types. By assembling studies exploring the intersection of unconventional cell death and CSC biology, we hope to gain deeper insights into innovative therapeutic avenues for combating cancer.
Join us in exploring cutting-edge research, aiming to unravel the complex relationships between alternative cell death modes and cancer stem cells, ultimately paving the way for novel therapeutic strategies.
Dr. Mun-Ock Kim
Prof. Dr. Shazib Pervaiz
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer stem cell
- alternative cell death mode
- tumor microenvironment
- immune mechanism
- cellular basis of cancer therapy resistance
- cellular transformation
- small-molecule-based therapeutics
